[{"orgOrder":0,"company":"Vector Pharma","sponsor":"Oncopeptides","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Melphalan Flufenamide","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Vector Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vector Pharma \/ Vector Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Vector Pharma \/ Vector Pharma"},{"orgOrder":0,"company":"Vector Pharma","sponsor":"Oncopeptides","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Melphalan Flufenamide","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Vector Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vector Pharma \/ Vector Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Vector Pharma \/ Vector Pharma"},{"orgOrder":0,"company":"Vector Pharma","sponsor":"R-Pharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.A.E","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Ixabepilone","moa":"||Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Vector Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vector Pharma \/ R-Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Vector Pharma \/ R-Pharm"},{"orgOrder":0,"company":"Vector Pharma","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.A.E","productType":"Hormone","year":"2024","type":"Agreement","leadProduct":"Lonapegsomatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Vector Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vector Pharma \/ Ascendis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Vector Pharma \/ Ascendis Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Vector Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Vector will distribute Skytrofa (lonapegsomatropin-tcgd) for pediatric growth hormone deficiency and Yorvipath for adult hypoparathyroidism in the GCC countries, using its sales expertise.

                          Product Name : Skytrofa

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          August 01, 2024

                          Lead Product(s) : Lonapegsomatropin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Ascendis Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Under the collaboration, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, to patients in the MENA region for patients with multiple myeloma.

                          Product Name : Pepaxti

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          March 30, 2024

                          Lead Product(s) : Melphalan Flufenamide,Dexamethasone

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Recipient : Oncopeptides

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Under the agreement, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, in the MENA region for the treatment of patients with multiple myeloma.

                          Product Name : Pepaxti

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          March 27, 2024

                          Lead Product(s) : Melphalan Flufenamide,Dexamethasone

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Recipient : Oncopeptides

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Under the agreement, R-PHARM US has appointed Vector Pharma as exclusive distributor to import, use, market, sell and distribute Ixempra (ixabepilone) in the Middle East & North African territories.

                          Product Name : Ixempra

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 22, 2021

                          Lead Product(s) : Ixabepilone,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : R-Pharm

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank